IBIS Therapeutics, LLC has developed the Molecular Fingerprint Platform to evaluate interactions between diverse arrays of drug candidates with the largest curated collection of both disease-modifying and toxicity-causing protein targets.
IBIS Therapeutics, LLC has developed the Molecular Fingerprint Platform to evaluate interactions between diverse arrays of drug candidates with the largest curated collection of both disease-modifying and toxicity-causing protein targets.